{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T10:53:21Z","timestamp":1794135201100,"version":"4.8.0"},"reference-count":24,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Hematology"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/16078454.2026.2618403","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T08:28:14Z","timestamp":1770625694000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Switching patients with PNH from pegcetacoplan to iptacopan: a case series"],"prefix":"10.1080","volume":"31","author":[{"given":"Mark","family":"Orland","sequence":"first","affiliation":[{"name":"Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, OH, USA"},{"name":"University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasa","family":"Sanikommu","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute","place":["Charlotte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01157"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003812"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2109462"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02047-z"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90250-t"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06240.x"},{"issue":"6","key":"e_1_3_4_8_1","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1182\/blood.V79.6.1400.1400","article-title":"Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes","volume":"79","author":"Mahoney JF","year":"1992","unstructured":"Mahoney JF, Urakaze M, Hall S, et al. Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes. Blood. 1992;79(6):1400\u20131403.","journal-title":"Blood"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01113-0"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2020.102528"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-522128"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01542-7"},{"key":"e_1_3_4_13_1","unstructured":"Soliris (eculizumab). Prescribing information. Alexion Pharmaceuticals."},{"key":"e_1_3_4_14_1","unstructured":"Ultomiris (ravulizumab). Prescribing information. Alexion Pharmaceuticals."},{"key":"e_1_3_4_15_1","unstructured":"Piasky (crovalimab-akkz). Prescribing information. Genentech Incorporated."},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015490"},{"key":"e_1_3_4_17_1","unstructured":"Empaveli (pegcetacoplan). Prescribing information. Apellis Pharmaceuticals."},{"key":"e_1_3_4_18_1","unstructured":"Fabhalta (iptacopan). Prescribing information. Novartis Pharmaceuticals."},{"key":"e_1_3_4_19_1","unstructured":"Voydeya (danicopan). Prescribing information. Alexion Pharmaceuticals."},{"key":"e_1_3_4_20_1","unstructured":"Tomassetti S Kuypers N Paulose J et al. Poster presented at: AMCP 2025 Annual Meeting; March 31-April 3 2025; Houston TX."},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009129"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029073"},{"issue":"9","key":"e_1_3_4_23_1","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2352-3026(22)00210-1","article-title":"Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial","volume":"9","author":"Peffault de Latour R","year":"2022","unstructured":"Peffault de Latour R, Szer J, Weitz IC, et al. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Hematol. 2022;9(9):e648\u2013e659.","journal-title":"Lancet Hematol"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308695"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024023988"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/16078454.2026.2618403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T08:28:16Z","timestamp":1770625696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/16078454.2026.2618403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/16078454.2026.2618403"],"URL":"https:\/\/doi.org\/10.1080\/16078454.2026.2618403","relation":{},"ISSN":["1607-8454"],"issn-type":[{"value":"1607-8454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2618403"}}